home *** CD-ROM | disk | FTP | other *** search
/ Cancer - Principles & Practice of Oncology / Oncology.iso / PPO / CHAP53 / T8_4.GIF < prev    next >
Graphics Interchange Format  |  1999-06-07  |  168.5 KB  |  725x746  |  8-bit (240 colors)
   ocr: TABLE 53.8-4. Endometrial Cancer Risk After lamoxiten in Breast Cancer Endometrial Cancers Duration of 95% Breast In Tamoxifen Dosage Tamoxjen Comfidence Study Design Cancers Total Users Evaluated Use Relative Risk Interval Fornander Clinical trial 1846 15 13 40: mg 2-5y 6.4 1.4-28 cta al, 1989*186 Andersson Clinical trial 1710 9 7 30 mg 48wk 3.S 0.6-32.4 eta al, 1991*199 Van Leeuwen Case-control NA 98 23 20-40 mg Varied Any: 1.3 0.7-2.4 eta al, 22y: 2.3 0.9-5.9 1994200 Trend with duration: P=. .049 Fisher et al, Clinical trial 1063 24 23 20 mg Planned: Tamoxifen VS 1.7-32.7 1994175 25y contro ...